92 related articles for article (PubMed ID: 26376801)
61. The Herculean task of killing cancer cells: suppression of FOXO3A in acute leukemia involves a hydra of multiple survival kinases.
Ruvolo PP
Cell Cycle; 2012 Jul; 11(14):2589. PubMed ID: 22751430
[TBL] [Abstract][Full Text] [Related]
62. Retraction: IKBKE Phosphorylation and Inhibition of FOXO3a: A Mechanism of IKBKE Oncogenic Function.
PLOS ONE Editors
PLoS One; 2023; 18(7):e0289330. PubMed ID: 37490498
[No Abstract] [Full Text] [Related]
63. Nuclear Localization Marker of FOXO3a: Can it be Used to Predict Doxorubicin Response?
Gong C; Khoo US
Front Oncol; 2013; 3():149. PubMed ID: 23761862
[No Abstract] [Full Text] [Related]
64. Glucocorticoid-Induced Leucine Zipper Is Expressed in Human Neutrophils and Promotes Apoptosis through Mcl-1 Down-Regulation.
Espinasse MA; Pépin A; Virault-Rocroy P; Szely N; Chollet-Martin S; Pallardy M; Biola-Vidamment A
J Innate Immun; 2016; 8(1):81-96. PubMed ID: 26384220
[TBL] [Abstract][Full Text] [Related]
65. TRIM6 promotes glioma malignant progression by enhancing FOXO3A ubiquitination and degradation.
Guo J; Wang J; Zhang P; Wen P; Zhang S; Dong X; Dong J
Transl Oncol; 2024 Aug; 46():101999. PubMed ID: 38759605
[TBL] [Abstract][Full Text] [Related]
66. The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia.
Shah K; Ahmed M; Kazi JU
NPJ Precis Oncol; 2021 Feb; 5(1):13. PubMed ID: 33597638
[TBL] [Abstract][Full Text] [Related]
67. FOXO transcription factor family in cancer and metastasis.
Jiramongkol Y; Lam EW
Cancer Metastasis Rev; 2020 Sep; 39(3):681-709. PubMed ID: 32372224
[TBL] [Abstract][Full Text] [Related]
68. Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases.
Liao C; Zhang Q
Am J Pathol; 2020 Aug; 190(8):1584-1595. PubMed ID: 32339495
[TBL] [Abstract][Full Text] [Related]
69. Integrated bioinformatics analysis of the crucial candidate genes and pathways associated with glucocorticoid resistance in acute lymphoblastic leukemia.
Chen Y; Jiang P; Wen J; Wu Z; Li J; Chen Y; Wang L; Gan D; Chen Y; Yang T; Lin M; Hu J
Cancer Med; 2020 Apr; 9(8):2918-2929. PubMed ID: 32096603
[TBL] [Abstract][Full Text] [Related]
70. EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer.
Mahmud Z; Gomes AR; Lee HJ; Aimjongjun S; Jiramongkol Y; Yao S; Zona S; Alasiri G; Gong G; Yagüe E; Lam EW
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31357743
[TBL] [Abstract][Full Text] [Related]
71. The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance.
Yao S; Fan LY; Lam EW
Semin Cancer Biol; 2018 Jun; 50():77-89. PubMed ID: 29180117
[TBL] [Abstract][Full Text] [Related]
72. Blunting Autoantigen-induced FOXO3a Protein Phosphorylation and Degradation Is a Novel Pathway of Glucocorticoids for the Treatment of Systemic Lupus Erythematosus.
Lu M; Xu W; Gao B; Xiong S
J Biol Chem; 2016 Sep; 291(38):19900-12. PubMed ID: 27481940
[TBL] [Abstract][Full Text] [Related]
73. MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy.
Polak A; Kiliszek P; Sewastianik T; Szydłowski M; Jabłońska E; Białopiotrowicz E; Górniak P; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Nowis D; Gołąb J; Giebel S; Lech-Marańda E; Warzocha K; Juszczyński P
PLoS One; 2016; 11(5):e0155893. PubMed ID: 27196001
[TBL] [Abstract][Full Text] [Related]
74. Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal.
Xie M; Yang A; Ma J; Wu M; Xu H; Wu K; Jin Y; Xie Y
Cell Death Dis; 2019 Jan; 9(10):1013. PubMed ID: 30598523
[TBL] [Abstract][Full Text] [Related]
75. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
[TBL] [Abstract][Full Text] [Related]
76. Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies.
Yang A; Ma J; Wu M; Qin W; Zhao B; Shi Y; Jin Y; Xie Y
Leuk Lymphoma; 2012 Dec; 53(12):2465-73. PubMed ID: 22582938
[TBL] [Abstract][Full Text] [Related]
77. Deciphering the role of forkhead transcription factors in cancer therapy.
Yang JY; Hung MC
Curr Drug Targets; 2011 Aug; 12(9):1284-90. PubMed ID: 21443462
[TBL] [Abstract][Full Text] [Related]
78. FOXO3a-interacting proteins' involvement in cancer: a review.
Dong Z; Guo Z; Li H; Han D; Xie W; Cui S; Zhang W; Huang S
Mol Biol Rep; 2024 Jan; 51(1):196. PubMed ID: 38270719
[TBL] [Abstract][Full Text] [Related]
79. FOXO3a and Posttranslational Modifications Mediate Glucocorticoid Sensitivity in B-ALL.
Consolaro F; Ghaem-Maghami S; Bortolozzi R; Zona S; Khongkow M; Basso G; Viola G; Lam EW
Mol Cancer Res; 2015 Dec; 13(12):1578-90. PubMed ID: 26376801
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
